TFPI
Tissue factor pathway inhibitor
As of the edition of 20 October 2026, TFPI (tissue factor pathway inhibitor, UniProt P10646) has 4 drugs tested at it and 5 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10646
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 9
- Disease areas
- Blood and lymph; Inherited and neonatal; Heart and blood vessels
- Registered trials of its drugs
- 45
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Andexanet alfa | Marketed | Phase 4 | Ends 2030 |
| Concizumab | Marketed | Phase 3 | Ends 2036 |
| Marstacimab | Marketed | Phase 3 | Ends 2036 |
| BAY-1093884 | Stopped | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Novo Nordisk | Route B |
| Bayer | Route A |
The other 2 companies at TFPI
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at TFPI, ranked, with the facts behind eachRequest access. Nothing is shown until you do.